The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Focus on epithelial ovarian cancer
Open accessAbstract
Epithelial ovarian cancer (EOC) will be diagnosed in 24,400women in the United States in 2004, with an estimated 14,300deaths (Jemal et al., 2003).Neoplasms from the surface epithe-lium of the ovary exhibit a variety of Mullerian-type cells, includ-ing serous, mucinous, endometrioid, and clear cell, reflecting acommon pathway in embryological development.In the westernworld, EOC is the most lethal gynecologic cancer, accountingfor more deaths than endometrial and cervical cancer com-bined. Spread of the disease via the lymphatics and by peri-toneal implantation is not associated with any specific signs orsymptoms, and the vast majority of women are diagnosed withdisseminated intraperitoneal carcinomatosis (FIGO Stage III).Also contributing to the high mortality is the advanced age atdiagnosis (median 63 years), with an increase aftermenopause. While ultrasound and computerized tomogramsare useful in definition of sites of bulk disease, surgical evalua-tion is necessary for accurate staging and to remove largemetastases (cytoreduction). Due to the propensity for diffusesmall-volume disease, surgery is rarely able to render patientsdisease free, and postoperative chemotherapy is usuallyrequired. While overall mortality rates have remained relativelyconstant for the past two to three decades, five-year survivalrates have increased from 30% in the 1960s to over 50% in thepast several years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Use of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Self-citationStructure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Self-citationThe causes and prevention of cancer.
Ames, B. N., Gold, L. S., & Willett, W. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5258 · Cited by 1,319
Biallelic Inactivation of BRCA2 in Fanconi Anemia
Howlett, N. G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., de Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G., et al. (2002) · Science · doi:10.1126/science.1073834 · Cited by 1,149
INCESSANT OVULATION—A FACTOR IN OVARIAN NEOPLASIA ?
Fathalla, M. F. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92335-x · Cited by 1,119
Cited by
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293
Loessner, D., Stok, K. S., Lutolf, M. P., Hutmacher, D. W., Clements, J. A., & Rizzi, S. C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.064 · Cited by 602
Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D., & Jacks, T. (2005) · Nature Medicine · doi:10.1038/nm1173 · Cited by 604
Drapkin, R., von Horsten, H. H., Lin, Y., Mok, S. C., Crum, C. P., Welch, W. R., & Hecht, J. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3924 · Cited by 570
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412
Metadata
- Authors
- Ozols, R. F., Bookman, M. A., Connolly, D. C., Daly, M. B., Godwin, A. K., Schilder, R. J., Xu, X., & Hamilton, T. C.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2004-01
- Volume
- 5
- Issue
- 1
- Pages
- 19-24
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2013896443
- Cited by
- 294
- References
- 35
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Focus on epithelial ovarian cancer. https://app.cochat.ai/papers/10.1016/s1535-6108(04)00002-9
- The paper
- Ozols, R. F., Bookman, M. A., Connolly, D. C., Daly, M. B., Godwin, A. K., Schilder, R. J., Xu, X., & Hamilton, T. C. (2004). Focus on epithelial ovarian cancer. Cancer Cell. https://doi.org/10.1016/s1535-6108(04)00002-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.